APYX vs HRTX

APYX exhibits a weak Piotroski F-Score of 1/9, signaling significant financial distress and poor operational health, with negative ROE, ROA, and high debt/equity. Despite this, the company demonstrates strong revenue growth (34.7% YoY) and a compelling earnings surprise history, with recent quarters beating estimates by an average of 33.74%. The stock is trading at a premium valuation (Price/Book: 10.43, Price/Sales: 2.82) but is supported by a strong analyst consensus of 'strong_buy' and a target price of $6.40, implying significant upside. Insider activity remains neutral, but the recent 1-year return of +249% reflects strong market momentum. The absence of a Graham Number and Altman Z-Score limits fundamental safety checks, but growth expectations appear to justify the valuation premium.

HRTX presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of positive technical momentum (0/100). While the company maintains strong gross margins (72.64%) and a healthy current ratio (2.48), these are overshadowed by an extreme Debt/Equity ratio of 9.81 and a catastrophic 5-year price decline of 94.8%. There is a severe disconnect between the 'Strong Buy' analyst consensus with a $4.33 target and the actual market performance and fundamental leverage.